Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed
Read More Pharma Industry News Is setmelanotide the first true disease-targeted therapy for hypothalamic obesity? Is setmelanotide redefining hypothalamic obesity treatment? Explore what Rhythm Pharmaceuticals, Inc.’s EU approval means for markets and growth. bySoujanya RaviMay 4, 2026